Vyvanse Bed denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for vyvanse bed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Vyvanse for BED as Non-Formulary

Blue Cross Blue Shield formulary structures vary significantly across plan types (HMO, PPO, employer-sponsored, Marketplace), and Vyvanse is placed at different tiers — or excluded entirely — depending on the specific plan variant. A non-formulary denial means the plan either does not include Vyvanse at any tier for the BED indication, or the plan requires a formulary exception process before it will cover a non-preferred agent. This is distinct from a medical-necessity denial: the plan may accept that the medication is clinically appropriate while still insisting you demonstrate that no formulary alternative is adequate.

## Why This Denial Is Appealable

The ACA and most state insurance regulations require that plans have a meaningful exceptions process when no formulary alternative is clinically appropriate. Because Vyvanse holds the only FDA-approved indication for moderate-to-severe BED in its drug class, there may be no therapeutically equivalent formulary substitute — which is precisely the argument a formulary exception appeal should make. Mental Health Parity rules may also be relevant if the formulary management for BED medications is more restrictive than for comparable non-behavioral conditions.

## Federal Appeal Framework

• Formulary exception request — submit before or in parallel with the formal appeal; BCBS plans are required to have an exceptions process.
• Internal appeal — file within the deadline on your denial notice (commonly 180 days).
• External review (ACA §2719) — fully-insured plans must allow external review of coverage denials including formulary exceptions; approximately four months from final internal denial.
• ERISA §503 — self-funded employer plans must provide full-and-fair review with written rationale.
• Expedited track — request if a standard timeline poses a serious health risk.

## Documentation to Gather

1. Diagnosis and severity documentation — clinician records confirming moderate-to-severe BED per DSM-5. 2. Formulary alternative trial history — if any formulary alternatives exist, document that they were tried and were ineffective or caused intolerance, with dates and outcomes. If none exist, your prescriber should state that explicitly. 3. Prescriber medical-necessity / exception letter — a letter stating that no formulary alternative is therapeutically equivalent for your confirmed BED diagnosis and explaining the clinical rationale for Vyvanse specifically. 4. FDA prescribing label — confirming the labeled BED indication. 5. Plan's formulary and exception criteria — obtain the current formulary document and the exception criteria from your plan's member portal or customer service; address each criterion directly.

## Criteria-Mapping Structure

Locate BCBS's formulary exception policy criteria for your specific plan. List each criterion (e.g., clinical appropriateness, lack of suitable formulary alternative, prior failure of formulary agents). For each, place the criterion on the left and the supporting documentation on the right. The strongest argument is typically a clear statement that no formulary drug shares the FDA-approved BED indication — making a therapeutic substitute unavailable by definition — paired with your prescriber's clinical rationale.